TNF Pharmaceuticals Inc (Nasdaq: TNFA), a clinical stage biopharmaceutical company developing novel oral therapies for autoimmune and inflammatory conditions, on Wednesday announced positive clinical data supporting the expansion of its Phase 2b study for isomyosamine, its novel TNF-alpha (TNF-α) inhibitor drug, into multiple indications.
The company has successfully completed an FDA-recommended safety study, which showed favorable results over 13 weeks at all dose levels.
TNFA plans to initiate a Phase 2b clinical trial in early 2025 to assess the efficacy of isomyosamine in treating sarcopenia, a market expected to reach USD4.02bn by 2029. Additionally, the company will launch a study to evaluate isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty in patients using GLP-1 agonists like Wegovy or Ozempic, targeting a rapidly growing USD105bn market by 2029.
Isomyosamine, a novel small molecule, modulates inflammatory cytokines including TNF-α, which plays a key role in aging and various age-related diseases. The TNF inhibitor market alone is projected to reach USD47.3bn by 2029.
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma